X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUN PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUN PHARMA DISHMAN PHARMA/
SUN PHARMA
 
P/E (TTM) x 25.1 15.0 167.0% View Chart
P/BV x 3.3 3.5 94.7% View Chart
Dividend Yield % 0.7 0.2 306.3%  

Financials

 DISHMAN PHARMA   SUN PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUN PHARMA
Mar-16
DISHMAN PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,201 31.2%   
Low Rs129706 18.2%   
Sales per share (Unadj.) Rs197.8117.5 168.4%  
Earnings per share (Unadj.) Rs21.219.6 108.2%  
Cash flow per share (Unadj.) Rs34.723.8 145.8%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.80.1 757.8%  
Book value per share (Unadj.) Rs179.9130.5 137.9%  
Shares outstanding (eoy) m80.692,406.60 3.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.38.1 15.7%   
Avg P/E ratio x11.948.7 24.4%  
P/CF ratio (eoy) x7.240.1 18.1%  
Price / Book Value ratio x1.47.3 19.1%  
Dividend payout %9.45.1 184.8%   
Avg Mkt Cap Rs m20,3062,294,813 0.9%   
No. of employees `0000.814.7 5.6%   
Total wages/salary Rs m5,35547,971 11.2%   
Avg. sales/employee Rs Th19,252.719,169.8 100.4%   
Avg. wages/employee Rs Th6,459.53,253.0 198.6%   
Avg. net profit/employee Rs Th2,064.13,197.9 64.5%   
INCOME DATA
Net Sales Rs m15,961282,697 5.6%  
Other income Rs m2656,170 4.3%   
Total revenues Rs m16,226288,867 5.6%   
Gross profit Rs m4,10383,239 4.9%  
Depreciation Rs m1,09110,135 10.8%   
Interest Rs m9444,769 19.8%   
Profit before tax Rs m2,33474,505 3.1%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m1-19 -5.9%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m6249,349 6.7%   
Profit after tax Rs m1,71147,159 3.6%  
Gross profit margin %25.729.4 87.3%  
Effective tax rate %26.712.5 213.0%   
Net profit margin %10.716.7 64.3%  
BALANCE SHEET DATA
Current assets Rs m11,018308,646 3.6%   
Current liabilities Rs m9,517132,477 7.2%   
Net working cap to sales %9.462.3 15.1%  
Current ratio x1.22.3 49.7%  
Inventory Days Days11083 133.2%  
Debtors Days Days3588 39.7%  
Net fixed assets Rs m16,304133,606 12.2%   
Share capital Rs m1612,407 6.7%   
"Free" reserves Rs m12,907266,909 4.8%   
Net worth Rs m14,516314,042 4.6%   
Long term debt Rs m4,18931,167 13.4%   
Total assets Rs m29,805542,196 5.5%  
Interest coverage x3.516.6 20.9%   
Debt to equity ratio x0.30.1 290.8%  
Sales to assets ratio x0.50.5 102.7%   
Return on assets %8.99.6 93.0%  
Return on equity %11.815.0 78.5%  
Return on capital %17.517.8 98.8%  
Exports to sales %24.814.0 177.1%   
Imports to sales %3.73.1 118.9%   
Exports (fob) Rs m3,95639,572 10.0%   
Imports (cif) Rs m5968,882 6.7%   
Fx inflow Rs m4,95242,171 11.7%   
Fx outflow Rs m69721,583 3.2%   
Net fx Rs m4,25520,588 20.7%   
CASH FLOW
From Operations Rs m2,78667,694 4.1%  
From Investments Rs m-1,529-44,549 3.4%  
From Financial Activity Rs m-941-19,243 4.9%  
Net Cashflow Rs m3163,902 8.1%  

Share Holding

Indian Promoters % 61.4 63.7 96.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.1 72.1%  
FIIs % 12.7 23.0 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 8.3 266.3%  
Shareholders   46,261 133,026 34.8%  
Pledged promoter(s) holding % 35.8 0.5 6,747.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; Auto Stocks Witness Selling(01:30 pm)

After opening the day flat, share markets in India continued to witness selling pressure and are currently trading in red. Sectoral indices are trading on a mixed note with stocks in the metals sector.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS